Omeros stock maintains Buy rating at H.C. Wainwright on EU submission

Investing.com - H.C. Wainwright reiterated its Buy rating and $9.00 price target on Omeros Corp . (NASDAQ:OMER) following the company’s recent regulatory submission in Europe. The target represents significant upside from the current price of $3.20, though InvestingPro analysis indicates the stock is currently trading below its Fair Value.

Omeros announced on June 27 that it submitted its marketing authorization application to the European Medicines Agency for narsoplimab, its treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The development comes as the $187.5M market cap company faces challenges with cash burn and significant debt levels.

The submission represents a significant milestone for Omeros as it seeks regulatory approval for narsoplimab in the European market, complementing its ongoing efforts to secure approval in the United States.

H.C. Wainwright analyst Brandon Folkes maintained the firm’s positive outlook on Omeros, suggesting the stock may be entering a phase of re-rating over the next 12 months driven by potential approvals in both the U.S. and EU markets.

The analyst also noted that approval could lead to "subsequent re-appreciation" of the company’s other pipeline programs once Omeros reinvests in development efforts beyond narsoplimab.

In other recent news, Omeros Corporation has submitted a Marketing Authorization Application to the European Medicines Agency for its drug narsoplimab, aimed at treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The application highlights a 61% response rate and improved overall survival among patients. Concurrently, the U.S. Food and Drug Administration has accepted Omeros’ resubmitted Biologics License Application for the same drug, with an expected decision date in September 2025. In financial news, Omeros reported a net loss of $33.5 million, or $0.58 per share, for the first quarter of 2025, aligning with analyst expectations. The company also reduced its total debt by $10 million, while OMIDRIA royalties contributed $6.7 million to its earnings. The strategic focus on debt reduction and product development positions Omeros for potential future growth, as noted by analysts. Additionally, the company is actively preparing for the commercial launch of narsoplimab, targeting key transplant centers.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.